These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

895 related articles for article (PubMed ID: 16004667)

  • 1. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
    Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H
    Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of advanced Parkinson's disease in the United States: a cost-utility model.
    Groenendaal H; Tarrants ML; Armand C
    Clin Drug Investig; 2010; 30(11):789-98. PubMed ID: 20818839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson's disease in the UK.
    Lowin J; Bergman A; Chaudhuri KR; Findley LJ; Roeder C; Schifflers M; Wood E; Morris S
    J Med Econ; 2011; 14(5):584-93. PubMed ID: 21728911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
    Lowin J; Sail K; Baj R; Jalundhwala YJ; Marshall TS; Konwea H; Chaudhuri KR
    J Med Econ; 2017 Nov; 20(11):1207-1215. PubMed ID: 28895769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment.
    Brooks DJ; Agid Y; Eggert K; Widner H; Ostergaard K; Holopainen A;
    Eur Neurol; 2005; 53(4):197-202. PubMed ID: 15970632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The clinical-pharmacoeconomic study of efficacy of stalevo in the treatment of Parkinson's disease with motor fluctuations].
    Levin OS; Smolentseva IG; Fedorova NV; Chigir' IP; Dokadina LV; Makhnev SO
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(7):27-34. PubMed ID: 18833115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany.
    Walter E; Odin P
    J Med Econ; 2015 Feb; 18(2):155-65. PubMed ID: 25348011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States.
    Palmer CS; Nuijten MJ; Schmier JK; Subedi P; Snyder EH
    Pharmacoeconomics; 2002; 20(9):617-28. PubMed ID: 12141889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.
    Hauser RA; Panisset M; Abbruzzese G; Mancione L; Dronamraju N; Kakarieka A;
    Mov Disord; 2009 Mar; 24(4):541-50. PubMed ID: 19058133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson's disease in patients in Scotland and Wales.
    Kalabina S; Belsey J; Pivonka D; Mohamed B; Thomas C; Paterson B
    J Med Econ; 2019 Mar; 22(3):215-225. PubMed ID: 30484353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis.
    Nuijten MJ; van Iperen P; Palmer C; van Hilten BJ; Snyder E
    Value Health; 2001; 4(4):316-28. PubMed ID: 11705299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study].
    Litvinenko IV; Odinak MM; Mogil'naia VI; Sologub OS; Sakharovskaia AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(1):51-4. PubMed ID: 19156087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.
    Hudry J; Rinne JO; Keränen T; Eckert L; Cochran JM
    Ann Pharmacother; 2006 Apr; 40(4):651-7. PubMed ID: 16569799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
    Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
    Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacoeconomic aspects of combined treatment of advanced stage of Parkinson's disease].
    Rudakova AV; Levin OS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6. Vyp. 2):96-100. PubMed ID: 28980620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off.
    Koller W; Guarnieri M; Hubble J; Rabinowicz AL; Silver D
    J Neural Transm (Vienna); 2005 Feb; 112(2):221-30. PubMed ID: 15503197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness.
    Noyes K; Dick AW; Holloway RG;
    Pharmacoeconomics; 2005; 23(12):1257-70. PubMed ID: 16336019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson's disease.
    Martínez-Martín P; Hernández B; Ricart J;
    Neurologia; 2014 Apr; 29(3):153-60. PubMed ID: 23465686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson's disease patients treated with levodopa/carbidopa.
    Hansen RN; Suh K; Serbin M; Yonan C; Sullivan SD
    J Med Econ; 2021; 24(1):563-569. PubMed ID: 33866942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased dose of carbidopa with levodopa and entacapone improves "off" time in a randomized trial.
    Trenkwalder C; Kuoppamäki M; Vahteristo M; Müller T; Ellmén J
    Neurology; 2019 Mar; 92(13):e1487-e1496. PubMed ID: 30824559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.